• Originator EMD Serono; Merck Biopharma; Merck KGaA
• Developer 4SC; AIO Studien gGmbH; Array BioPharma; Baylor College of Medicine; Chong Kun Dang; Dana-Farber Cancer Institute; Debiopharm; eFFECTOR Therapeutics; EMD Serono; Forty Seven; Fred Hutchinson Cancer Research Center; G1 Therapeutics; Gachon University Gil Medical Center; Hellenic Cooperative Oncology Group; Hoosier Cancer Research Network; Hospices Civils de Lyon; Istituto Oncologico Veneto; Johannes Gutenberg-University Mainz; M. D. Anderson Cancer Center; Merck Biopharma; Merck KGaA; National Cancer Institute (USA); Netherlands Cancer Institute; Pfizer; Seoul National University Hospital; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Syndax Pharmaceuticals; Transgene; University College London; University of Birmingham; University of California, San Diego; University of Iowa; University of North Carolina at Chapel Hill; University of Padua; Vaccinex; Vanderbilt-Ingram Cancer Center; VAXIMM; Verastem Oncology; Washington University School of Medicine
• Class Antineoplastics; Immunotherapies; Monoclonal antibodies
• Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants

• Orphan Drug Status

  Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  Yes - Merkel cell carcinoma; Gastric cancer
• New Molecular Entity Yes

Highest Development Phases

• Marketed Merkel cell carcinoma; Renal cell carcinoma; Urogenital cancer
• Phase III Colorectal cancer; Diffuse large B cell lymphoma; Gastric cancer; Head and neck cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Triple negative breast cancer
• Phase II Bladder cancer; Breast cancer; Endometrial cancer; Fallopian tube cancer; Gastrointestinal cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Gestational trophoblastic disease; Glioblastoma; Haemangiosarcoma; HER2 negative breast cancer; HER2 positive breast cancer; Hodgkin's disease; Intestinal cancer; Leiomyosarcoma; Liver cancer; Lymphoma; Malignant thymoma; Nasopharyngeal cancer; Neuroendocrine tumours; Non-small cell lung cancer; Osteosarcoma; Penile cancer; Peripheral T-cell lymphoma; Peritoneal cancer; Prostate cancer; Rectal cancer; Recurrent respiratory papillomatosis; Small cell lung cancer; Squamous cell cancer; Testicular cancer; Thymoma
• Phase I/II Anal cancer; Bone metastases; Cervical cancer; Liposarcoma; Oropharyngeal cancer; Pancreatic cancer; Vulvovaginal cancer
• No development reported Acute myeloid leukaemia; CNS cancer; Follicular lymphoma; Meningioma

Most Recent Events

• 28 Jan 2025 No recent reports of development identified for phase-I development in CNS-cancer(Combination therapy, In adolescents, In children, In infants, Late-stage disease, Second-line therapy or greater, In adults) in France (IV, Infusion)
• 28 Jan 2025 No recent reports of development identified for phase-I development in CNS-cancer(Combination therapy, In adolescents, In children, In infants, Late-stage disease, Second-line therapy or greater, In adults) in Germany (IV, Infusion)
• 28 Jan 2025 No recent reports of development identified for phase-I development in CNS-cancer(Combination therapy, In adolescents, In children, In infants, Late-stage disease, Second-line therapy or greater, In adults) in South Korea (IV, Infusion)